USA - New York Stock Exchange - NYSE:PHR - US71944F1066 - Common Stock
The current stock price of PHR is 17.44 USD. In the past month the price decreased by -15.03%. In the past year, price decreased by -35.38%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 30.99 | 39.43B | ||
| DOCS | DOXIMITY INC-CLASS A | 28.38 | 8.76B | ||
| WAY | WAYSTAR HOLDING CORP | 24.87 | 6.38B | ||
| HTFL | HEARTFLOW INC | N/A | 2.79B | ||
| CERT | CERTARA INC | 19.15 | 1.53B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.37B | ||
| SDGR | SCHRODINGER INC | N/A | 1.39B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 642 | 1.09B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.07B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 8.31 | 987.74M | ||
| HSTM | HEALTHSTREAM INC | 33.31 | 672.03M | ||
| CTEV | CLARITEV CORP | N/A | 529.62M |
Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The company is headquartered in Wilmington, Delaware and currently employs 2,082 full-time employees. The company went IPO on 2019-07-18. The firm's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The firm's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
PHREESIA INC
1521 Concord Pike, Suite 301 Pmb 221
Wilmington DELAWARE 27601 US
CEO: Chaim Indig
Employees: 2082
Phone: 18886547473
Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The company is headquartered in Wilmington, Delaware and currently employs 2,082 full-time employees. The company went IPO on 2019-07-18. The firm's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The firm's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
The current stock price of PHR is 17.44 USD. The price increased by 1.16% in the last trading session.
PHR does not pay a dividend.
PHR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
PHR stock is listed on the New York Stock Exchange exchange.
PHREESIA INC (PHR) operates in the Health Care sector and the Health Care Technology industry.
PHREESIA INC (PHR) will report earnings on 2026-03-10, after the market close.
ChartMill assigns a fundamental rating of 4 / 10 to PHR. The financial health of PHR is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months PHR reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 93.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.27% | ||
| ROE | -1.68% | ||
| Debt/Equity | 0.01 |
21 analysts have analysed PHR and the average price target is 30.42 USD. This implies a price increase of 74.43% is expected in the next year compared to the current price of 17.44.
For the next year, analysts expect an EPS growth of 116.67% and a revenue growth 14.48% for PHR